NVO catalyst calendar

NOVO NORDISK A S

Upcoming catalysts
31
Cash runway
Cash generating
Cash & investments
DKK 26464M
Phase 3 programs
51

NOVO NORDISK A S is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.

The next scheduled catalyst is Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected) on December 13, 2026. There are 31 upcoming events on record.

NOVO NORDISK A S generates cash from operations, so a burn-based runway figure does not apply.

Across 431 concluded trials, 95% reached completion rather than being terminated or withdrawn.

Upcoming catalysts

DateEventTypePhase
December 13, 2026 Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected) Trial Milestone Phase 1
December 31, 2026 A Study Understanding How Much CDR132L Enters the Bloodstream After Injection Under the Skin Compared to Injection Into a Vein in Healthy Participants Trial Milestone Phase 1
January 14, 2027 A Research Study on How Well Different Doses of the Medicine UBT251 Help People Living With Overweight or Obesity Trial Milestone Phase 2
January 15, 2027 A Research Study on the Effects of NNC0537-1482 in Participants With Heart Failure Trial Milestone Phase 1
January 21, 2027 A Study to See How Safe a New Medicine (NNC6989-0001) is in Healthy People Living With Overweight or Obesity Trial Milestone Phase 1
January 26, 2027 A Study Looking at How Weekly Injections of Two Hormones - GIP and Amylin - Affect Stomach-related Side Effects in People Who Are Overweight or Obese Trial Milestone Phase 1
January 31, 2027 A Research Study Investigating How a New Medicine NNC0113-5840 Works in People With Overweight or Obesity Trial Milestone Phase 1
April 7, 2027 A Research Study on How UBT251 Affects Levels of Midazolam, Caffeine and Warfarin in the Blood of Participants With Excess Body Weight Trial Milestone Phase 1
June 9, 2027 Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema Trial Milestone Phase 3
July 6, 2027 A Research Study Looking Into How a Single Dose of the Medicine NNC0537-1482 Moves Through the Body of Participants With Normal or Reduced Kidney Function Trial Milestone Phase 1
September 1, 2027 REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels Trial Milestone Phase 3
September 3, 2027 A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes Trial Milestone Phase 2
September 12, 2027 A Study to See How Safe a New Medicine (NNC0642-1895) is in Healthy People Trial Milestone Phase 1
October 4, 2027 A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes Trial Milestone Phase 2
November 16, 2027 A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy Trial Milestone Phase 2
December 1, 2027 A Research Study Looking Into Blood Levels of the Medicine NNC0487-0111 in the Body and How Well it is Tolerated in People With Reduced Liver Function and Normal Liver Function Trial Milestone Phase 1
January 19, 2028 A Research Study Looking at How NNC0487-0111 Affects Food Intake, Appetite and Metabolism After Meals in People With Obesity Trial Milestone Phase 1
February 18, 2028 A Research Study Investigating the Effect of NNC0497-0040 in Healthy Participants, Participants With Overweight or Obesity, and Participants With Type 1 Diabetes With Overweight or Obesity Trial Milestone Phase 1
February 22, 2028 Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight Trial Milestone Phase 3
February 23, 2028 A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight Trial Milestone Phase 3
February 29, 2028 A Research Study to Look at Long-term Treatment With a Medicine Called NNC6019-0001 for People Who Have Heart Failure Due to Transthyretin Amyloidosis Trial Milestone Phase 2
July 31, 2028 AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications Trial Milestone Phase 3
August 14, 2028 AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain Trial Milestone Phase 3
August 28, 2028 A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity Trial Milestone Phase 3
September 6, 2028 A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Semaglutide Medication Trial Milestone Phase 1
October 10, 2028 A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide Trial Milestone Phase 3
November 14, 2028 A Research Study to Look at the Effect of Ziltivekimab on Plaque in the Blood Vessels of the Heart, Compared to Placebo, in People With a Heart Attack Trial Milestone Phase 3
November 15, 2028 STEP TEENS Weight Maintenance: A Research Study on How Well Semaglutide Helps Teenagers With Excess Body Weight to Lose Weight and Maintain Weight Loss Trial Milestone Phase 4
June 26, 2029 AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight Trial Milestone Phase 3
July 23, 2029 A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity Trial Milestone Phase 3
December 30, 2030 A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia Trial Milestone Phase 3

Track NVO alongside other companies. Add it to a watchlist and see every catalyst on one calendar.

Open NVO in the tracker

Recent history

DateEventTypePhase
October 13, 2026 6-K filed: Foreign issuer report Filing —
October 6, 2026 6-K filed: Foreign issuer report Filing —
October 5, 2026 6-K filed: Foreign issuer report Filing —
October 1, 2026 A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation Trial Milestone Phase 3
September 28, 2026 6-K filed: Foreign issuer report Filing —
September 21, 2026 6-K filed: Foreign issuer report Filing —
September 17, 2026 6-K filed: Foreign issuer report Filing —
September 15, 2026 6-K filed: Foreign issuer report Filing —
September 12, 2026 A Study to See the Effect of NNC0194-0499 Alone or in Combination With Semaglutide on Blood Sugar Control in People Living With Type 1 Diabetes Trial Milestone Phase 1
September 9, 2026 6-K filed: Foreign issuer report Filing —
September 3, 2026 A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation Trial Milestone Phase 3
August 31, 2026 6-K filed: Foreign issuer report Filing —
August 24, 2026 6-K filed: Foreign issuer report Filing —
August 18, 2026 6-K filed: Foreign issuer report Filing —
August 10, 2026 6-K filed: Foreign issuer report Filing —
August 10, 2026 6-K filed: Foreign issuer report Filing —
August 4, 2026 6-K filed: Foreign issuer report Filing —
August 4, 2026 6-K filed: Foreign issuer report Filing —
August 4, 2026 6-K filed: Foreign issuer report Filing —
July 31, 2026 6-K filed: Foreign issuer report Filing —
July 27, 2026 6-K filed: Foreign issuer report Filing —
July 21, 2026 6-K filed: Foreign issuer report Filing —
July 20, 2026 A Study on How NNC0174-1213 Works in People With Overweight or Obesity. Trial Milestone Phase 1
July 13, 2026 6-K filed: Foreign issuer report Filing —
July 6, 2026 6-K filed: Foreign issuer report Filing —
June 29, 2026 6-K filed: Foreign issuer report Filing —
June 24, 2026 6-K filed: Foreign issuer report Filing —
June 15, 2026 6-K filed: Foreign issuer report Filing —
June 8, 2026 6-K filed: Foreign issuer report Filing —
June 1, 2026 6-K filed: Foreign issuer report Filing —

About this data

Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.

Last updated 2026-10-14.